Amgen, Watson will develop follow-on biologics for cancer

12/19/2011 | Wall Street Journal, The

Amgen will team up with Watson Pharmaceuticals to develop and commercialize follow-on versions of several antibody biotech drugs for cancer, excluding Amgen's products. Amgen will be in charge of development, production and initial marketing. Watson will provide as much as $400 million for product development and contribute its commercialization and marketing know-how.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care